Immunovant, Inc.

XNASHealth care

Last traded price · USD

$29.48

+1.52%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:28 IST · A quote does not mean the product is available to trade on your account.

Day's open: $29.82
Previous close: $29.04
Volume: 1.3M
Day's high: $29.93
Day's low: $28.50

In brief

Immunovant, Inc. is a health care company listed on Nasdaq, valued at about $6.09B.
Its shares closed at $29.90 on 4 Nov 2026, up 23.6% over the past year.
From India you can buy IMVT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Immunovant, Inc. (IMVT) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole IMVT share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade IMVT options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY, behind its sector fund XLV over 1 year
1 month: −6.9% (SPY −1.6%, XLV +13.5%). 3 months: −23.9% (SPY −0.4%, XLV +15.5%). 1 year: +23.6% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IMVT, SPY and XLV · as of 4 Nov 2026
12.3 days to cover short interest
18.3M shares were sold short at the 15 Oct 2026 settlement, 8.8% of the 206.6M shares outstanding; covering them would take 12.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $29.90 was 11.2% below its 50-day average ($33.68) and 6.8% below its 200-day average ($32.09). It has closed below the 200-day for 20 sessions, since 8 Oct 2026. The 50-day average crossed above the 200-day on 3 Nov 2025, 252 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
35% of the way up its 52-week range
Closed at $29.90 on 4 Nov 2026: 34.2% below the 52-week high of $45.42 (19 Aug 2026) and 39.5% above the low of $21.43 (10 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−6.9%

6 months+4.3%

1 year+23.6%

5 years+242.9%

Newswire

About

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Website

Notable moves

May 20, 2026
+35.26%
September 26, 2023
+97.04%
October 4, 2022
+23.98%

Newswire

About

Website

Notable moves

May 20, 2026
+35.26%
September 26, 2023
+97.04%
October 4, 2022
+23.98%

Immunovant, Inc.

XNASHealth care

Last traded price · USD

$29.48

+1.52%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:28 IST · A quote does not mean the product is available to trade on your account.

Day's open: $29.82
Previous close: $29.04
Volume: 1.3M
Day's high: $29.93
Day's low: $28.50

In brief

Immunovant, Inc. is a health care company listed on Nasdaq, valued at about $6.09B.
Its shares closed at $29.90 on 4 Nov 2026, up 23.6% over the past year.
From India you can buy IMVT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Immunovant, Inc. (IMVT) shares from India?

Do I need the price of a whole IMVT share to invest?

How much can I invest in US stocks in a year?

Can I trade IMVT options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY, behind its sector fund XLV over 1 year
1 month: −6.9% (SPY −1.6%, XLV +13.5%). 3 months: −23.9% (SPY −0.4%, XLV +15.5%). 1 year: +23.6% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IMVT, SPY and XLV · as of 4 Nov 2026
12.3 days to cover short interest
18.3M shares were sold short at the 15 Oct 2026 settlement, 8.8% of the 206.6M shares outstanding; covering them would take 12.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $29.90 was 11.2% below its 50-day average ($33.68) and 6.8% below its 200-day average ($32.09). It has closed below the 200-day for 20 sessions, since 8 Oct 2026. The 50-day average crossed above the 200-day on 3 Nov 2025, 252 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
35% of the way up its 52-week range
Closed at $29.90 on 4 Nov 2026: 34.2% below the 52-week high of $45.42 (19 Aug 2026) and 39.5% above the low of $21.43 (10 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−6.9%

6 months+4.3%

1 year+23.6%

5 years+242.9%

Newswire

About

Website

Notable moves

May 20, 2026
+35.26%
September 26, 2023
+97.04%
October 4, 2022
+23.98%

Newswire

About

Website

Notable moves

May 20, 2026
+35.26%
September 26, 2023
+97.04%
October 4, 2022
+23.98%

Immunovant, Inc.

Immunovant, Inc. in brief

Ahead of SPY, behind its sector fund XLV over 1 year

12.3 days to cover short interest

Below its 50- and 200-day averages

35% of the way up its 52-week range

Immunovant, Inc.

Immunovant, Inc. in brief

Ahead of SPY, behind its sector fund XLV over 1 year

12.3 days to cover short interest

Below its 50- and 200-day averages

35% of the way up its 52-week range